Beta-Blocker Therapy for Varices in Cirrhosis

Primary Prophylaxis

The American Association for the Study of Liver Diseases recommends starting beta-blockers in patients with cirrhosis who have medium or large esophageal varices, or small varices with high-risk features, such as Child-Pugh B/C or red wale marks on endoscopy, to prevent first variceal hemorrhage 1, 2
Carvedilol is preferred over traditional non-selective beta-blockers due to its dual mechanism, which reduces both splanchnic blood flow and intrahepatic resistance, resulting in superior portal pressure reduction, with a significant reduction in progression from small to large varices (20.6% vs. 38.6% with placebo, p=0.04) 6, 3
The choice between beta-blockers and endoscopic variceal ligation (EVL) depends on patient characteristics, with those having Child-Pugh B/C or red wale marks on varices being at highest risk and should definitely receive treatment 2, 5

The recommended starting dose of carvedilol is 6.25 mg once daily, increasing to 6.25 mg twice daily after 3 days, with a maximum dose of 12.5 mg/day, aiming to maintain systolic blood pressure ≥90 mmHg 1, 3
Propranolol should be started at 20-40 mg twice daily, adjusting every 2-3 days to target heart rate 55-60 bpm, with a maximum dose of 320 mg/day without ascites and 160 mg/day with ascites, ensuring systolic blood pressure does not decrease <90 mmHg 1

Refractory ascites and spontaneous bacterial peritonitis are not absolute contraindications to beta-blocker therapy, but require careful dose management, avoiding high doses (>160 mg/day propranolol or >80 mg/day nadolol) associated with worse outcomes 7
Beta-blockers should be reduced or temporarily held in patients with severe circulatory dysfunction, such as systolic blood pressure <90 mmHg, serum sodium <130 mEq/L, or hepatorenal syndrome, and may be reintroduced after correction of circulatory dysfunction 7

Patients on beta-blockers do not require surveillance endoscopy, but should continue beta-blockers indefinitely, as bleeding risk recurs when stopped, with the American Association for the Study of Liver Diseases recommending lifelong therapy 1, 2
Patients on EVL should have repeat EVL every 1-2 weeks until variceal obliteration, with first surveillance endoscopy 1-3 months after obliteration, and subsequent endoscopy every 6-12 months to check for recurrence, as recommended by the American Association for the Study of Liver Diseases 5